Today: 5 February 2026
Subscribe
Browse Category

Biotech News News 25 November 2025 - 8 December 2025

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck & Co., Inc. (NYSE: MRK) is back in the spotlight. As of the afternoon of December 8, 2025, Merck shares trade around $98–99, down about 1% on the day and modestly below their recent 52‑week high of $105.84 reached in late November. That pullback comes after a powerful rebound from a May low near $76, driven by excitement over…
8 December 2025
····
Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) ripped higher again on 5 December 2025, extending one of the most dramatic biotech rallies of the year after positive epilepsy data and a favorable pre‑NDA meeting with the FDA. By the closing bell on Friday, PRAX finished at $247.99, up 30.5% on the day, with a new 52‑week range of $26.70–$277.44 and a…
6 December 2025
·····
Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025

Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025

Published: December 5, 2025 Protara Therapeutics, Inc. (NASDAQ: TARA) is ending the week in dramatic fashion. After a string of positive clinical updates for its lead cell therapy TARA‑002, the company has tapped equity markets with a $75 million public offering that has sent the stock down roughly 20% today, even as Wall Street price targets still imply several‑fold upside…
5 December 2025
·····
IonQ Stock Jumps After Quantum Breakthroughs and Biotech Deal: IONQ Price, Forecast and Outlook as of December 5, 2025

IonQ Stock Jumps After Quantum Breakthroughs and Biotech Deal: IONQ Price, Forecast and Outlook as of December 5, 2025

IonQ, Inc. (NYSE: IONQ) is once again at the center of the quantum-computing spotlight. After a sharp pullback in November, the quantum hardware specialist has ripped higher into early December on the back of record-breaking technical milestones, a new biotech partnership, and rising institutional interest. As of the close on December 4, 2025, IonQ stock finished at $54.76, up 12.6%…
5 December 2025
····
Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Updated December 5, 2025 – all developments since December 4, 2025 Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has moved back into the market spotlight after a flurry of major announcements on December 4, 2025. The biotech’s stock — already one of 2025’s wildest movers — is reacting to fresh positive data in rare epilepsies and new regulatory momentum for its…
5 December 2025
····
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. (NASDAQ: PLRZ) has exploded into the spotlight after a two‑day run that has turned an obscure micro‑cap biotech into one of the most talked‑about healthcare stocks on the Nasdaq. By early afternoon on December 4, 2025, Polyrizon shares were trading around $13–15, nearly doubling from Wednesday’s close at $7.09, with intraday highs reported above $18 and gains briefly…
4 December 2025
·····
Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

On December 2, 2025, Bristol-Myers Squibb (NYSE: BMY) found itself at the center of two very different storylines: a revived $6.7 billion Celgene lawsuit and strong hematology data at ASH 2025. Together with a hefty dividend and low valuation multiples, these cross-currents are shaping how investors see BMY stock heading into 2026. BMY Stock Snapshot on 2 December 2025 On…
3 December 2025
·····
Amgen Stock (AMGN) Today: Q3 2025 Earnings Beat, MariTide Obesity Drug Outlook and 2030 Price Forecast

Amgen Stock (AMGN) Today: Q3 2025 Earnings Beat, MariTide Obesity Drug Outlook and 2030 Price Forecast

Updated December 1, 2025 Amgen stock at a glance on December 1, 2025 Amgen Inc. (NASDAQ: AMGN) closed today at $337.49, down about 2.3% on the session, according to real‑time quote data. StockAnalysis Despite today’s pullback, the stock has had a powerful run: Zacks notes that Amgen shares are up almost 16% over the past month, significantly outpacing the broader…
1 December 2025
·····
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook

On December 1, 2025, Q32 Bio Inc. (NASDAQ: QTTB) suddenly became one of the most-watched small-cap biotech stocks on Wall Street. Shares of Q32 Bio surged intraday by roughly 90%–170% at various points in Monday’s session, with trading volume soaring from a typical few hundred thousand shares to tens or even hundreds of millions, after the company announced a major…
1 December 2025
······
AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie Inc. (NYSE: ABBV) ended Tuesday, November 25, 2025, on a firmer footing, closing at $231.80, up about 1.0% on the day and recovering some of Monday’s pullback. The move came amid a flurry of fresh headlines: U.S. Medicare confirmed plans to negotiate prices on 15 expensive drugs including an AbbVie product, AbbVie launched a new biotech award program in…
25 November 2025
···
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Key Takeaways ALT stock price today: how Altimmune is trading on November 25, 2025 Altimmune Inc. (NASDAQ: ALT) continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat to slightly higher versus Monday’s close. Intraday ranges have been tight so far, with trading largely clustered between about $4.8…
25 November 2025
·····
TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk

TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) had a busy news day on Monday — and the stock still finished sharply lower. Shares of the small-cap biotech closed around $14.29 on November 25, 2025, down roughly 11% on the session, putting the stock well below its recent highs despite a fresh U.S. FDA green light to advance a new depression treatment…
25 November 2025
····
1 … 7 8 9 10 11 12

Stock Market Today

  • Corn Futures Edge Higher Amid Export Sales and Ethanol Production Data
    February 5, 2026, 11:00 AM EST. Corn futures held slight gains midday, with cash corn prices up 1.25 cents to $3.95 1/2. A private export sale of 130,480 metric tons (MT) was reported to unknown destinations, while a South Korean importer bought 65,000 MT in a private tender. Ethanol production fell by 158,000 barrels per day (bpd) to 956,000 bpd last week, with stocks down 264,000 barrels. Exports rose 59,000 bpd. Traders anticipate USDA weekly sales data on Thursday, expecting 0.8-2.1 million MT sold for the week ending Jan. 29. March corn futures stood at $4.29 1/2, up 1 cent, with May and July 2026 contracts also posting modest gains. These moves reflect cautious optimism amid fluctuating demand and production shifts in related markets.
Go toTop